Dextran-coated superparamagnetic nanoparticles modified with folate for targeted drug delivery of camptothecin
Drug delivery vehicles based on magnetic nanoparticles present a promising strategy for cancer treatment, due to controlled targeted treatment, high loading efficiency, and biosafety as compared to traditional drug delivery approaches. In the present study, superparamagnetic iron oxide (Fe 3 O 4 ) n...
Gespeichert in:
Veröffentlicht in: | Advances in natural sciences. Nanoscience and nanotechnology 2020-12, Vol.11 (4), p.45009 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Drug delivery vehicles based on magnetic nanoparticles present a promising strategy for cancer treatment, due to controlled targeted treatment, high loading efficiency, and biosafety as compared to traditional drug delivery approaches. In the present study, superparamagnetic iron oxide (Fe
3
O
4
) nanoparticles (SPIONs) were synthesised by a co-precipitation approach, stabilised with dextran (DEX), and successfully conjugated with folate (FA) for delivery of camptothecin (CPT) in prostate cancer cells. Size and other characteristics of the modified nanoparticles were measured using scanning electron microscopy (SEM), transmission electron microscopy (TEM), dynamic light scattering (DLS), and zeta-potential. The results demonstrated that the prepared FA-DEX-SPIONs were spherical in shape with an average diameter of 63.31 nm. They had anticancer activity with high CPT loading efficiency in AT3B-1cancer cells, enabling the therapeutic activity of the drug via its active delivery and release at 37 °C in phosphate and citrate buffer solutions. MTT results exhibited no cytotoxicity on rat androgen independent prostate cancer (AT3B-1) and normal human prostate (RWPE-1) cells. In conclusion, FA-DEX-SPION composite is a promising candidate that could be used for the targeted release of CPT anti-cancer drug. |
---|---|
ISSN: | 2043-6262 2043-6254 2043-6254 2043-6262 |
DOI: | 10.1088/2043-6254/abc75b |